Skip to main content
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

July 17, 2012; 79 (3) Articles

GBA-associated PD

Neurodegeneration, altered membrane metabolism, and lack of energy failure

Kathrin Brockmann, Ruediger Hilker, Ulrich Pilatus, Simon Baudrexel, Karin Srulijes, Jörg Magerkurth, Ann-Kathrin Hauser, Claudia Schulte, Ilona Csoti, Caroline Denise Merten, Thomas Gasser, Daniela Berg, Elke Hattingen
First published June 20, 2012, DOI: https://doi.org/10.1212/WNL.0b013e31825dd369
Kathrin Brockmann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruediger Hilker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrich Pilatus
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon Baudrexel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karin Srulijes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jörg Magerkurth
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ann-Kathrin Hauser
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia Schulte
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ilona Csoti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Denise Merten
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Gasser
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Berg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elke Hattingen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
GBA-associated PD
Neurodegeneration, altered membrane metabolism, and lack of energy failure
Kathrin Brockmann, Ruediger Hilker, Ulrich Pilatus, Simon Baudrexel, Karin Srulijes, Jörg Magerkurth, Ann-Kathrin Hauser, Claudia Schulte, Ilona Csoti, Caroline Denise Merten, Thomas Gasser, Daniela Berg, Elke Hattingen
Neurology Jul 2012, 79 (3) 213-220; DOI: 10.1212/WNL.0b013e31825dd369

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
490

Share

  • Article
  • Figures & Data
  • Info & Disclosures
  • CME Course
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

Objective: To elucidate possible mechanisms leading to neurodegeneration in patients with glucocerebrosidase (GBA)–associated Parkinson disease (PD) using combined proton (1H) and phosphorus (31P) magnetic resonance spectroscopic imaging (MRSI) in vivo.

Methods: 1H and 1H-decoupled 31P MRSI was performed in 13 patients with PD with heterozygous GBA mutations (GBA-PD) and 19 age- and sex-matched healthy controls to investigate metabolite concentrations in the mesostriatal target regions of PD pathology. NAA as marker of neuronal integrity, choline and ethanolamine containing compounds as markers of membrane phospholipid metabolism, and energy metabolites (notably high-energy phosphates) were quantified.

Results: Compared to controls, NAA was significantly reduced in the putamen (p = 0.012) and in the midbrain of GBA-PD (p = 0.05). The choline concentration obtained from 1H MRSI was significantly decreased in the midbrain of GBA-PD (p = 0.010). The phospholipid degradation product glycerophosphoethalonamine was increased in the putamen of GBA-PD (p = 0.05). Changes of energy metabolism were not detected in any region of interest.

Conclusion: The pattern of neurodegeneration in GBA-associated PD is more pronounced in the putamen than in the midbrain. Our MRSI findings suggest that the neurodegenerative process in GBA-PD is associated with alterations of membrane phospholipid metabolism which might be also involved in abnormal α-synuclein aggregation.

GLOSSARY

ADP=
adenosine diphosphate;
ATP=
adenosine triphosphate;
CCT=
phosphocholine cytidylyltransferase;
Cr=
creatine;
ETS=
electron transport system;
GBA=
glucocerebrosidase;
GBA-PD=
patients with Parkinson disease with heterozygous GBA mutations;
GD=
Gaucher disease;
GM=
gray matter;
GPC=
glycerophosphocholine;
GPE=
glycerophosphoethalonamine;
1H=
proton;
HEP=
high-energy phosphate;
LB=
Lewy body;
LEP=
low-energy metabolite;
MPRAGE=
magnetization-prepared rapid gradient echo;
MRSI=
magnetic resonance spectroscopic imaging;
MSA=
multiple system atrophy;
NAA=
N-acetyl aspartate;
31P=
phosphorous;
PCho =
phosphocholine;
PCr =
phosphocreatine;
PD =
Parkinson disease;
PEth =
phosphoethanolamine;
Pi =
inorganic phosphate;
PtdCho =
phosphatidylcholine;
PtdSer =
phosphatidylserine;
SPM =
Statistical Parametric Mapping;
tCho =
total choline;
tCr =
total creatine;
TE =
echo time;
TR =
repetition time;
UPDRS-III =
motor part of the Unified Parkinson's Disease Rating Scale;
WM =
white matter

Footnotes

  • Study funding: The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007–2013) under grant agreement 241791 European Project on Mendelian Forms of Parkinson's Disease (MEFOPA).

  • Editorial, page 202.

  • Received August 20, 2011.
  • Accepted November 28, 2011.
  • Copyright © 2012 by AAN Enterprises, Inc.
View Full Text

AAN Members

We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.

Google Safari Microsoft Edge Firefox

Click here to login

AAN Non-Member Subscribers

Click here to login

Purchase access

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here 

Purchase
Individual access to articles is available through the Add to Cart option on the article page.  Access for 1 day (from the computer you are currently using) is US$ 39.00.  Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means.  The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use.  Distributing copies (electronic or otherwise) of the article is not allowed.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • GLOSSARY
    • METHODS
    • RESULTS
    • DISCUSSION
    • DISCLOSURE
    • AUTHOR CONTRIBUTIONS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
  • CME Course

More Online

CME Course

Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial

Dr. Jessica Ailani and Dr. Ailna Masters-Israilov

► Watch

Related Articles

  • Parkinson syndromeHeterogeneity of etiology; heterogeneity of pathogenesis?

Topics Discussed

  • All Clinical Neurology
  • All Genetics
  • Parkinson's disease/Parkinsonism
  • Basal ganglia
  • MRS

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Articles
    Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease
    L. N. Clark, B. M. Ross, Y. Wang et al.
    Neurology, September 17, 2007
  • Articles
    Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers
    M. Anheim, A. Elbaz, S. Lesage et al.
    Neurology, January 25, 2012
  • Brief Communications
    Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population
    M. Toft, L. Pielsticker, O. A. Ross et al.
    Neurology, February 13, 2006
  • Clinical/Scientific Notes
    GLUCOCEREBROSIDASE MUTATIONS IN 108 NEUROPATHOLOGICALLY CONFIRMED CASES OF MULTIPLE SYSTEM ATROPHY
    B. Segarane, A. Li, R. Paudel et al.
    Neurology, March 30, 2009
Neurology: 100 (23)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise